Key result
Specific reversal agents and prothrombin complex concentrates provide strategies for managing major bleeding on anticoagulants.
Why the study?
Physicians need updated knowledge of anticoagulation agents, reversal agents, and treatment strategies for managing major bleeding due to increasing anticoagulation options.
Provides a 2016 update on the clinical profiles of anticoagulation agents, reversal agents, and treatment strategies for major bleeding.
Offers 2016-era reversal options; leaves open need for updates with newer agents and trials.
Anticoagulation is the mainstay of medical treatment, prevention and reduction of recurrent venous thromboembolism, stroke prevention in patients with non-valvular atrial fibrillation, and it reduces the incidence of recurrent ischemic events and death in patients with acute coronary syndrome. Options for anticoagulation have been steadily increasing. Physicians need to be aware of the clinical profile of anticoagulation agents, reversal agents and treatment strategies in the face of major bleeding.
No takes yet. Share an insight, caveat, or question.
Christos et al. (2016) conducted a review in Major bleeding in patients on anticoagulants. Anticoagulation reversal strategies was evaluated. Specific reversal agents such as idarucizumab for dabigatran, along with prothrombin complex concentrates and supportive care, provide strategies for managing major bleeding in patients on anticoagulants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: